CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

EMA's CHMP Recommends Extensions Of Indication For Bexsero & Talzenna

By Reuters News

Nov 13 (Reuters) - EMA's CHMP:

  • EMA'S CHMP: RECOMMENDED EXTENDING USE OF GAZYVARO (OBINUTUZUMAB) TO TREAT ADULTS WITH MODERATE-TO-SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

  • EMA'S CHMP: RECOMMENDS GRANTING MARKETING AUTHORISATION FOR BAXFENDY

  • EMA'S CHMP: RECOMMENDED EXTENSIONS OF INDICATION FOR BEXSERO, COSENTYX, DOVATO, ENFLONSIA, STEGLATRO, SUNLENCA, TALZENNA, TIVICAY, WELIREG

  • EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR TALZENNA

  • EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR STEGLATRO

  • EMA'S CHMP: ADOPTED DHPC ABOUT POTENTIAL EFFECT OF MOUNJARO (TIRZEPATIDE) ON RELIABILITY OF ORAL CONTRACEPTIVES

  • EMA'S CHMP: DHPC REMINDS HEALTHCARE PROFESSIONALS THAT CONTRACEPTION IS RECOMMENDED FOR WOMEN WHO CAN BECOME PREGNANT & USING MOUNJARO

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk